Drugs / SNX-5422
SNX-5422
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 111 trials | ||||||
| Phase 1 | NCT02973399 | Feb 2017 → Dec 2018 | cancer | Esanex Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02914327 | Feb 2017 → Jul 2018 | cancer | Esanex Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01635712 | Feb 2014 → Jan 2016 | cancer | Esanex Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02063958 | Feb 2014 → Mar 2017 | cancer | Esanex Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01892046 | Nov 2013 → Feb 2017 | cancer | Esanex Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01851096 | Mar 2013 → Oct 2015 | cancer | Esanex Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01611623 | May → Nov 2012 | cancer | Esanex Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00644072 | Mar 2008 → Jun 2009 | lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00647764 | Mar 2008 → Sep 2010 | cancer, leukemia, lymphoma | Esanex Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00595686 | Jan 2008 → May 2010 | hematopoietic and lymphoid cell neoplasm | Esanex Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00506805 | Jun 2007 → Mar 2010 | cancer | Esanex Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01848756 | Apr 2013 → Feb 2015 | cancer | Esanex Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT02612285 | Mar → Oct 2016 | cancer | Esanex Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNX 5422 | “A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Erlotinib in Subjects With Lung Adenocarcinoma With "Acquired Resistance" to Epidermal Growth Factor Receptor...” NCT01851096 ↗ |
| Known as | Pf-04929113 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1195136 ↗ |
| Known as | Pf-4929113 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1195136 ↗ |
| Known as | SNX-5422 Mesylate | “SNX-5422 Mesylate Hsp90 inhibitor” NCT00647764 ↗ |
| Action | Inhibit | “SNX-5422 is an experimental drug that blocks Hsp90.” NCT00506805 ↗ |
| Modality | Small molecule | “SNX-5422 is a pro-drug of SNX-2112, a potent, highly selective, small-molecule inhibitor of the molecular chaperone heat shock protein 90 (Hsp90).” NCT01848756 ↗ |
| Route | Oral | “dose escalated, tablets every other day; undetermined duration until disease progression” NCT00506805 ↗ |